7th Workshop IRE on Translational Oncology : " Challenges and advances in drug resistance and tolerance in cancer" - 1
×
![]()
Professione e disciplina
- Medico chirurgo - Allergologia ed immunologia clinica
- Medico chirurgo - Anatomia patologica
- Medico chirurgo - Anestesia e rianimazione
- Medico chirurgo - Angiologia
- Medico chirurgo - Audiologia e foniatria
- Medico chirurgo - Biochimica clinica
- Medico chirurgo - Cardiochirurgia
- Medico chirurgo - Cardiologia
- Medico chirurgo - Chirurgia generale
- Medico chirurgo - Chirurgia maxillo-facciale
- Medico chirurgo - Chirurgia pediatrica
- Medico chirurgo - Chirurgia plastica e ricostruttiva
- Medico chirurgo - Chirurgia toracica
- Medico chirurgo - Chirurgia vascolare
- Medico chirurgo - Cure palliative
- Medico chirurgo - Continuit? assistenziale
- Medico chirurgo - Dermatologia e venereologia
- Medico chirurgo - Direzione medica di presidio ospedaliero
- Medico chirurgo - Ematologia
- Medico chirurgo - Endocrinologia
- Medico chirurgo - Epidemiologia
- Medico chirurgo - Farmacologia e tossicologia clinica
- Medico chirurgo - Gastroenterologia
- Medico chirurgo - Genetica medica
- Medico chirurgo - Geriatria
- Medico chirurgo - Ginecologia e ostetricia
- Medico chirurgo - Igiene degli alimenti e della nutrizione
- Medico chirurgo - Igiene, epidemiologia e sanita pubblica
- Medico chirurgo - Laboratorio di genetica medica
- Medico chirurgo - Malattie dell'apparato respiratorio
- Medico chirurgo - Malattie infettive
- Medico chirurgo - Malattie metaboliche e diabetologia
- Medico chirurgo - Medicina aeronautica e spaziale
- Medico chirurgo - Medicina del lavoro e sicurezza degli ambienti di lavoro
- Medico chirurgo - Medicina dello sport
- Medico chirurgo - Medicina e chirurgia di accettazione e di urgenza
- Medico chirurgo - Medicina fisica e riabilitazione
- Medico chirurgo - Medicina generale (medici di famiglia)
- Medico chirurgo - Medicina interna
- Medico chirurgo - Medicina legale
- Medico chirurgo - Medicina nucleare
- Medico chirurgo - Medicina termale
- Medico chirurgo - Medicina trasfusionale
- Medico chirurgo - Microbiologia e virologia
- Medico chirurgo - Nefrologia
- Medico chirurgo - Neonatologia
- Medico chirurgo - Neurochirurgia
- Medico chirurgo - Neurofisiopatologia
- Medico chirurgo - Neurologia
- Medico chirurgo - Neuropsichiatria infantile
- Medico chirurgo - Oftalmologia
- Medico chirurgo - Oncologia
- Medico chirurgo - Organizzazione dei servizi sanitari di base
- Medico chirurgo - Ortopedia e traumatologia
- Medico chirurgo - Otorinolaringoiatria
- Medico chirurgo - Patologia clinica (laboratorio di analisi chimico-cliniche e microbiologia)
- Medico chirurgo - Pediatria
- Medico chirurgo - Privo di specializzazione
- Medico chirurgo - Psichiatria
- Medico chirurgo - Psicoterapia
- Medico chirurgo - Radiodiagnostica
- Medico chirurgo - Radioterapia
- Medico chirurgo - Reumatologia
- Medico chirurgo - Scienza dell'alimentazione e dietetica
- Medico chirurgo - Urologia
Informazioni Corso
-
Normativa:
ECM Nazionale -
Obiettivo:
18 Contenuti tecnico-professionali (conoscenze e competenze) specifici di ciascuna professione, di ciascuna specializzazione e di ciascuna attività ultraspecialistica, ivi incluse le malattie rare e la medicina di genere
| Crediti: | 7.7 |
| Codice: | 461240 |
| Inizio corso: | 20/10/2025 - dalle: 11:00 |
| Fine corso: | 21/10/2025 - alle: 17:30 |
| Giorni corso previsti: | 2 |
| Totale Ore di formazione: | 11 |
| Posti Disponibili: | 199 |
| Iscrizioni: | dal: 01/08/2025 - al: 17/10/2025 |
| Quota partecipazione: | Gratuito |
Location
-
Aula A - Centro Congressi Bastianelli IFO, I.F.O. ISTITUTI FISIOTERAPICI OSPITALIERI
Via Ognibene 23 - Roma
Programma
20/10/2025
21/10/2025
11:00 - 11:30
Sima Lev
Session I
Session I
11:00 - 11:30
Oreste Segatto
Session I
Session I
11:30 - 12:00
Rene Bernards
Innovative approaches to fight cancer drug resistance
Innovative approaches to fight cancer drug resistance
12:00 - 12:30
Yardena Samuels
The various layers of intratumor heterogeneity and their impact on tumor immunity
The various layers of intratumor heterogeneity and their impact on tumor immunity
12:30 - 13:30
Anna Teresa Bagnato
Session II
Session II
12:30 - 13:30
Silvia Soddu
Session II
Session II
13:30 - 14:00
Trever Bivona
Insights into multifaceted mechanisms underlying drug tolerance and resistance in oncogene-driven NSCLC
Insights into multifaceted mechanisms underlying drug tolerance and resistance in oncogene-driven NSCLC
14:00 - 14:30
Alberto Bardelli
Targeting DNA mismatch repair for therapeutic purposes
Targeting DNA mismatch repair for therapeutic purposes
14:30 - 15:00
Yaara Oren
The day after the drug investigating drug-induced cellular memory
The day after the drug investigating drug-induced cellular memory
15:00 - 15:30
Fabio Calabro'
Session III
Session III
15:00 - 15:30
Paola Nistico'
Session III
Session III
15:30 - 16:00
Itai Yanai
Cellular adaptation to cancer therapy and the tumor microenvironment
Cellular adaptation to cancer therapy and the tumor microenvironment
16:00 - 16:30
Federico Cappuzzo
Immunotherapy in lung cancer
Immunotherapy in lung cancer
16:30 - 17:00
Fatima Mechta-grigoriou
Deciphering spatial heterogeneity of the stroma and immunosuppression in breast cancer
Deciphering spatial heterogeneity of the stroma and immunosuppression in breast cancer
17:00 - 17:30
Maurizio Scaltriti
Tumor adaptive response and resistance to therapy
Tumor adaptive response and resistance to therapy
21/10/2025
9:00 - 9:15
Eleonora Petti
Young investigator session
Young investigator session
9:00 - 9:15
Claudio Pulito
Young investigator session
Young investigator session
9:15 - 9:45
Jakub Abramson
Exploiting autoantibodies for cancer immunotherapy
Exploiting autoantibodies for cancer immunotherapy
9:45 - 10:00
Peng Jiang
Data-driven approaches to reveal secreted protein regulators of anti-tumor immune response
Data-driven approaches to reveal secreted protein regulators of anti-tumor immune response
10:00 - 10:15
Marta Di Martile
Targeting the Bcl-2 regulatory network to address immunotherapy resistance in preclinical melanoma models
Targeting the Bcl-2 regulatory network to address immunotherapy resistance in preclinical melanoma models
10:15 - 10:30
Annalisa Tocci
h-MENA regulated secretory autophagy mediates unconventional communication between CAFs and cancer cells contributing to immunotherapy resistance in NSCLC
h-MENA regulated secretory autophagy mediates unconventional communication between CAFs and cancer cells contributing to immunotherapy resistance in NSCLC
11:00 - 11:15
Piera Tocci
Targeting endothelin-1 receptor/PIEZO1 mechanosignaling to tackle drug resistance in high-grade serous ovarian cancer
Targeting endothelin-1 receptor/PIEZO1 mechanosignaling to tackle drug resistance in high-grade serous ovarian cancer
11:15 - 11:30
Sebastiano Vaccarella
High-throughput screening on organoid platforms: targeting cancer-associated fibroblasts to overcome resistance in endometrial carcinoma
High-throughput screening on organoid platforms: targeting cancer-associated fibroblasts to overcome resistance in endometrial carcinoma
11:30 - 11:45
Valentina Bruno
Fertility sparing treatments response prediction in young women to preserve reproductive chances: unraveling immune-mutational pathways for resistance in endometrial cancer
Fertility sparing treatments response prediction in young women to preserve reproductive chances: unraveling immune-mutational pathways for resistance in endometrial cancer
11:15 - 12:00
Maria Consiglia Ferriero
Drug resistance in genito-urinary malignancies: treatment options for bcg unresponsive bladder cancer and castration resistant prostate cancer
Drug resistance in genito-urinary malignancies: treatment options for bcg unresponsive bladder cancer and castration resistant prostate cancer
12:00 - 13:00
Luca Quagliata
The drug resistance market landscape: understanding the business drivers
The drug resistance market landscape: understanding the business drivers
13:00 - 14:00
Gennaro Ciliberto
Session IV
Session IV
12:00 - 13:00
Maurizio Fanciulli
Session IV
Session IV
14:00 - 14:30
Andrea Alimonti
Reprogramming the cold prostate tumor microenvironment as an actionable target for cancer therapy
Reprogramming the cold prostate tumor microenvironment as an actionable target for cancer therapy
14:30 - 15:00
Eytan Ruppin
Towards fast and accessible precision oncology
Towards fast and accessible precision oncology
15:00 - 15:30
Lillian Siu
Multi-omic interrogation of primary and acquired immune resistance
Multi-omic interrogation of primary and acquired immune resistance
15:30 - 17:00
Anna Mondino
Session V Round table. Breaking barriers: advancing clinical trials to tackle drug resistance in cancer
Session V Round table. Breaking barriers: advancing clinical trials to tackle drug resistance in cancer
15:30 - 17:00
Eytan Ruppin
Session V Round table. Breaking barriers: advancing clinical trials to tackle drug resistance in cancer
Session V Round table. Breaking barriers: advancing clinical trials to tackle drug resistance in cancer
15:30 - 17:00
Yardena Samuels
Session V Round table. Breaking barriers: advancing clinical trials to tackle drug resistance in cancer
Session V Round table. Breaking barriers: advancing clinical trials to tackle drug resistance in cancer
15:30 - 17:00
Maurizio Scaltriti
Session V Round table. Breaking barriers: advancing clinical trials to tackle drug resistance in cancer
Session V Round table. Breaking barriers: advancing clinical trials to tackle drug resistance in cancer
15:30 - 17:00
Lillian Siu
Session V Round table. Breaking barriers: advancing clinical trials to tackle drug resistance in cancer
Session V Round table. Breaking barriers: advancing clinical trials to tackle drug resistance in cancer
17:00 - 17:30
Giovanni Blandino
Closing remarks
Closing remarks
17:00 - 17:30
Eytan Ruppin
Closing remarks
Closing remarks